{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T23:44:30Z","timestamp":1767311070431,"version":"3.48.0"},"publisher-location":"Cham","reference-count":103,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032076854","type":"print"},{"value":"9783032076861","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-07686-1_11","type":"book-chapter","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T23:39:49Z","timestamp":1767310789000},"page":"223-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving Therapeutic Approaches for Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients"],"prefix":"10.1007","author":[{"given":"Stanley C.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Ammerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Vo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"5","key":"11_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/00007890-198305000-00006","volume":"35","author":"NH Allen","year":"1983","unstructured":"Allen NH, Dyer P, Geoghegan T, Harris K, Lee HA, Slapak M (1983) Plasma exchange in acute renal allograft rejection. A controlled trial. Transplantation 35(5):425\u2013428. https:\/\/doi.org\/10.1097\/00007890-198305000-00006","journal-title":"Transplantation"},{"issue":"17","key":"11_CR2","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s40265-020-01418-5","volume":"80","author":"ZT Al-Salama","year":"2020","unstructured":"Al-Salama ZT (2020) Imlifidase: first approval. Drugs 80(17):1859\u20131864. https:\/\/doi.org\/10.1007\/s40265-020-01418-5","journal-title":"Drugs"},{"issue":"7","key":"11_CR3","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/ajt.15366","volume":"19","author":"WM Baldwin 3rd","year":"2019","unstructured":"Baldwin WM 3rd, Valujskikh A, Fairchild RL (2019) The neonatal Fc receptor: key to homeostasic control of IgG and IgG-related biopharmaceuticals. Am J Transplant 19(7):1881\u20131887. https:\/\/doi.org\/10.1111\/ajt.15366","journal-title":"Am J Transplant"},{"key":"11_CR4","first-page":"698","volume":"31","author":"V Bonomini","year":"1985","unstructured":"Bonomini V, Vangelista A, Frasc\u00e0 GM, Di Felice A, Liviano D\u2019AG (1985) Effects of plasmapheresis in renal transplant rejection. A controlled study. Trans Am Soc Artif Intern Organs 31:698\u2013703","journal-title":"Trans Am Soc Artif Intern Organs"},{"issue":"5","key":"11_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14936","volume":"37","author":"B Boonpheng","year":"2023","unstructured":"Boonpheng B, De Castro ICC, Ng YH, Blosser C, Bakthavatsalam R, Gimferrer I, Smith K, Leca N (2023) Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients. Clin Transpl 37(5):e14936. https:\/\/doi.org\/10.1111\/ctr.14936. Epub 2023 Feb 24","journal-title":"Clin Transpl"},{"issue":"6","key":"11_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115832","volume":"44","author":"R Chen","year":"2025","unstructured":"Chen R, Powell JS, Shufesky WJ, Bardhi E, Sullivan MLG, Tkacheva OA, Camirand G, Goncalves Z, Stolz DB, Chalasani G, Catz SD, Watkins SC, Larregina AT, Morelli AE (2025) Transplants foster B cell alloimmunity by relaying extracellular vesicles to follicular dendritic cells. Cell Rep 44(6):115832. https:\/\/doi.org\/10.1016\/j.celrep.2025.115832","journal-title":"Cell Rep"},{"issue":"9","key":"11_CR7","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/ajt.14228","volume":"17","author":"J Choi","year":"2017","unstructured":"Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, Kim I, Louie S, Kang A, Peng A, Kahwaji J, Reinsmoen N, Toyoda M, Jordan SC (2017) Assessment of Tocilizumab (anti-Interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant Glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 17(9):2381\u20132389. https:\/\/doi.org\/10.1111\/ajt.14228. Epub 2017 Mar 10","journal-title":"Am J Transplant"},{"issue":"11","key":"11_CR8","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/ajt.14328","volume":"17","author":"N Chun","year":"2017","unstructured":"Chun N, Fairchild RL, Li Y et al (2017) Complement dependence of murine costimulatory blockade-resistant cellular cardiac allograft rejection. Am J Transplant 17(11):2810\u20132819. https:\/\/doi.org\/10.1111\/ajt.14328","journal-title":"Am J Transplant"},{"issue":"5","key":"11_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/txd.0000000000001139","volume":"7","author":"M Daligault","year":"2021","unstructured":"Daligault M, Bardy B, Noble J et al (2021) Marginal impact of Tocilizumab monotherapy on anti-HLA alloantibodies in highly sensitized kidney transplant candidates. Transplant Direct 7(5):e690. https:\/\/doi.org\/10.1097\/txd.0000000000001139","journal-title":"Transplant Direct"},{"issue":"2","key":"11_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/tp.0000000000004689","volume":"108","author":"AE de Weerd","year":"2024","unstructured":"de Weerd AE, Roelen DL, van de Wetering J, Betjes HS, Reinders MEJ (2024) Imlifidase desensitization in HLA-incompatible kidney transplantation: finding the sweet spot. Transplantation 108(2):335\u2013345. https:\/\/doi.org\/10.1097\/tp.0000000000004689","journal-title":"Transplantation"},{"issue":"4","key":"11_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/TP.0000000000005187","volume":"109","author":"M Diebold","year":"2025","unstructured":"Diebold M, Mayer KA, Hidalgo L, Kozakowski N, Budde K, B\u00f6hmig GA (2025) Chronic rejection after kidney transplantation. Transplantation 109(4):610\u2013621. https:\/\/doi.org\/10.1097\/TP.0000000000005187. Epub 2024 Aug 28","journal-title":"Transplantation"},{"issue":"3","key":"11_CR12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1681\/asn.2020071106","volume":"32","author":"K Doberer","year":"2021","unstructured":"Doberer K, Duerr M, Halloran PF et al (2021) A randomized clinical trial of anti\u2013IL-6 antibody Clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 32(3):708\u2013722. https:\/\/doi.org\/10.1681\/asn.2020071106","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"11_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/TP.0000000000003754","volume":"106","author":"MJ Eerhart","year":"2022","unstructured":"Eerhart MJ, Reyes JA, Blanton CL et al (2022) Complement blockade in recipients prevents delayed graft function and delays antibody-mediated rejection in a nonhuman primate model of kidney transplantation. Transplantation 106(1):60\u201371. https:\/\/doi.org\/10.1097\/TP.0000000000003754","journal-title":"Transplantation"},{"issue":"5","key":"11_CR14","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/ajt.14222","volume":"17","author":"CR Ensor","year":"2017","unstructured":"Ensor CR, Yousem SA, Marrari M et al (2017) Proteasome inhibitor Carfilzomib-based therapy for antibody-mediated rejection of the pulmonary allograft: use and short-term findings. Am J Transplant 17(5):1380\u20131388. https:\/\/doi.org\/10.1111\/ajt.14222","journal-title":"Am J Transplant"},{"issue":"2","key":"11_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1681\/asn.2017070818","volume":"29","author":"F Eskandary","year":"2018","unstructured":"Eskandary F, Regele H, Baumann L et al (2018a) A randomized trial of Bortezomib in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 29(2):591\u2013605. https:\/\/doi.org\/10.1681\/asn.2017070818","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"11_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/ajt.14528","volume":"18","author":"F Eskandary","year":"2018","unstructured":"Eskandary F, Jilma B, Muhlbacher J et al (2018b) Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial. Am J Transplant 18(4):916\u2013926. https:\/\/doi.org\/10.1111\/ajt.14528","journal-title":"Am J Transplant"},{"issue":"Suppl 1","key":"11_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.03955.x","volume":"157","author":"E Fern\u00e1ndez-Cruz","year":"2009","unstructured":"Fern\u00e1ndez-Cruz E, Alecsandru D, S\u00e1nchez Ram\u00f3n S, Ram\u00f3n SS (2009) Mechanisms of action of immune globulin. Clin Exp Immunol 157(Suppl 1):1\u20132. https:\/\/doi.org\/10.1111\/j.1365-2249.2009.03955.x","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"11_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.15232","volume":"182","author":"CL Freeman","year":"2018","unstructured":"Freeman CL, Sehn LH (2018) A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol 182(1):29\u201345. https:\/\/doi.org\/10.1111\/bjh.15232","journal-title":"Br J Haematol"},{"issue":"10","key":"11_CR19","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/j.1600-6143.2006.01497","volume":"6","author":"H Genberg","year":"2006","unstructured":"Genberg H, Hansson A, Wernerson A, Wennberg L, Tyd\u00e9n G (2006) Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 6(10):2418\u20132428. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01497","journal-title":"Am J Transplant"},{"issue":"8","key":"11_CR20","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1034\/j.1600-6143.2003.00180.x","volume":"3","author":"JM Gloor","year":"2003","unstructured":"Gloor JM, DeGoey SR, Pineda AA et al (2003) Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 3(8):1017\u20131023. https:\/\/doi.org\/10.1034\/j.1600-6143.2003.00180.x","journal-title":"Am J Transplant"},{"issue":"6","key":"11_CR21","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/MNH.000000000000","volume":"23","author":"C Gosset","year":"2014","unstructured":"Gosset C, Lefaucheur C, Glotz D (2014) New insights in antibody-mediated rejection. Curr Opin Nephrol Hypertens 23(6):597\u2013604. https:\/\/doi.org\/10.1097\/MNH.000000000000","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"7","key":"11_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.15383","volume":"38","author":"F Halleck","year":"2024","unstructured":"Halleck F, B\u00f6hmig GA, Couzi L et al (2024) A randomized trial comparing Imlifidase to plasmapheresis in kidney transplant recipients with antibody-mediated rejection. Clin Transpl 38(7):e15383. https:\/\/doi.org\/10.1111\/ctr.15383","journal-title":"Clin Transpl"},{"key":"11_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14337","volume":"35","author":"A Hart","year":"2021","unstructured":"Hart A, Schladt DP, Matas AJ et al (2021a) Incidence, risk factors, and long-term outcomes associated with antibody-mediated rejection\u2014the long-term deterioration of kidney allograft function (DeKAF) prospective cohort study. Clin Transpl 35:e14337","journal-title":"Clin Transpl"},{"key":"11_CR24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1080\/13696998.2021.1964267","volume":"24","author":"A Hart","year":"2021","unstructured":"Hart A, Zaun D, Itzler R et al (2021b) Cost, healthcare utilization, and outcomes of antibody-mediated rejection in kidney transplant recipients in the US. J Med Econ 24:1011\u20131017","journal-title":"J Med Econ"},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41581-023-00791-030069","volume":"20","author":"PS Heeger","year":"2024","unstructured":"Heeger PS, Haro MC, Jordan SC (2024) Translating B cell immunology to the treatment of antibody-mediated allograft rejection. Nat Rev Nephrol 20:218\u2013232. https:\/\/doi.org\/10.1038\/s41581-023-00791-030069","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"11_CR26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","volume":"37","author":"YA Heo","year":"2023","unstructured":"Heo YA (2023) Efgartigimod Alfa in generalised myasthenia gravis: a profile of its use. CNS Drugs 37(5):467\u2013473. https:\/\/doi.org\/10.1007\/s40263-023-01000-z","journal-title":"CNS Drugs"},{"issue":"3","key":"11_CR27","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ajt.2022.11.001","volume":"23","author":"JA Hill","year":"2023","unstructured":"Hill JA, Kiem ES, Bhatti A et al (2023) Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy. Am J Transplant 23(3):416\u2013422. https:\/\/doi.org\/10.1016\/j.ajt.2022.11.001","journal-title":"Am J Transplant"},{"issue":"23","key":"11_CR28","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/wnl.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr, Bril V, Burns TM et al (2019) Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92(23):e2661\u2013e2673. https:\/\/doi.org\/10.1212\/wnl.0000000000007600","journal-title":"Neurology"},{"issue":"14","key":"11_CR29","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s40265-023-01933-1","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023) Rozanolixizumab: first approval. Drugs 83(14):1341\u20131347. https:\/\/doi.org\/10.1007\/s40265-023-01933-1","journal-title":"Drugs"},{"issue":"1","key":"11_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2215\/CJN.04840419","volume":"15","author":"E Huang","year":"2020","unstructured":"Huang E, Vo A, Choi J et al (2020) Three-year outcomes of a randomized, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients. Clin J Am Soc Nephrol 15(1):109\u2013116. https:\/\/doi.org\/10.2215\/CJN.04840419","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"11_CR31","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/ajt.16828","volume":"22","author":"E Huang","year":"2022","unstructured":"Huang E, Maldonado AQ, Kjellman C, Jordan SC (2022) Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation. Am J Transplant 22(3):691\u2013697. https:\/\/doi.org\/10.1111\/ajt.16828","journal-title":"Am J Transplant"},{"issue":"5","key":"11_CR32","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16(5):448\u2013457. https:\/\/doi.org\/10.1038\/ni.3153","journal-title":"Nat Immunol"},{"key":"11_CR33","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/TP.0000000000003274","volume":"105","author":"W Irish","year":"2021","unstructured":"Irish W, Nickerson P, Astor BC et al (2021) Change in estimated GFR and risk of allograft failure in patients diagnosed with late active antibody-mediated rejection following kidney transplantation. Transplantation 105:648\u2013659","journal-title":"Transplantation"},{"issue":"10","key":"11_CR34","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1111\/ajt.15881","volume":"20","author":"D Jain","year":"2020","unstructured":"Jain D, Rajab A, Young JS et al (2020) Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients. Am J Transplant 20(10):2675\u20132685. https:\/\/doi.org\/10.1111\/ajt.15881","journal-title":"Am J Transplant"},{"issue":"10","key":"11_CR35","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.healun.2023.05.012","volume":"42","author":"SE January","year":"2023","unstructured":"January SE, Fester KA, Halverson LP, Witt CA, Byers DE, Vazquez-Guillamet R, Alexander-Brett J, Tague LK, Kreisel D, Gelman A, Puri V, Bahena RN, Takahashi T, Hachem RR, Kulkarni HS (2023) Tocilizumab for antibody-mediated rejection treatment in lung transplantation. J Heart Lung Transplant 42(10):1353\u20131357. https:\/\/doi.org\/10.1016\/j.healun.2023.05.012. Epub 2023 Jun 1. PMID: 37268051; PMCID: PMC10529998","journal-title":"J Heart Lung Transplant"},{"key":"11_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.688301","volume":"12","author":"N Joher","year":"2021","unstructured":"Joher N, Matignon M, Grimbert P (2021) HLA desensitization in solid organ transplantation: anti-CD38 to across the immunological barriers. Front Immunol 12:688301. https:\/\/doi.org\/10.3389\/fimmu.2021.688301","journal-title":"Front Immunol"},{"issue":"12","key":"11_CR37","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","volume":"15","author":"SC Jordan","year":"2004","unstructured":"Jordan SC, Tyan D, Stablein D et al (2004) Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 15(12):3256\u20133262. https:\/\/doi.org\/10.1097\/01.ASN.0000145878.92906.9F","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"11_CR38","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/MOT.0b013e32834874f7","volume":"16","author":"SC Jordan","year":"2011","unstructured":"Jordan SC, Kahwaji J, Toyoda M, Vo A (2011) B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr Opin Organ Transplant 16(4):416\u2013424. https:\/\/doi.org\/10.1097\/MOT.0b013e32834874f7","journal-title":"Curr Opin Organ Transplant"},{"issue":"17","key":"11_CR39","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMc1711335","volume":"377","author":"SC Jordan","year":"2017","unstructured":"Jordan SC, Lorant T, Choi J (2017) IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med 377(17):1693\u20131694. https:\/\/doi.org\/10.1056\/NEJMc1711335","journal-title":"N Engl J Med"},{"issue":"12","key":"11_CR40","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1111\/ajt.14767","volume":"18","author":"SC Jordan","year":"2018","unstructured":"Jordan SC, Choi J, Aubert O et al (2018) A phase I\/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients. Am J Transplant 18(12):2955\u20132964. https:\/\/doi.org\/10.1111\/ajt.14767","journal-title":"Am J Transplant"},{"issue":"suppl 3","key":"11_CR41","first-page":"1062","volume":"19","author":"SC Jordan","year":"2019","unstructured":"Jordan SC, Toyoda M, Ammerman N, Huang E, Peng A, Sethi S, Najjar R, Lim K, Vo A (2019) Daratumumab for treatment of antibody-mediated rejection in a kidney transplant recipient. Am J Transplant 19(suppl 3):1062","journal-title":"Am J Transplant"},{"issue":"1","key":"11_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/TP.0000000000002912","volume":"104","author":"SC Jordan","year":"2020","unstructured":"Jordan SC, Ammerman N, Vo A (2020) Implications of Fc neonatal receptor (FcRn) manipulations for transplant Immunotherapeutics. Transplantation 104(1):17\u201323. https:\/\/doi.org\/10.1097\/TP.0000000000002912","journal-title":"Transplantation"},{"issue":"8","key":"11_CR43","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1097\/TP.0000000000003496","volume":"105","author":"SC Jordan","year":"2021","unstructured":"Jordan SC, Legendre C, Desai NM et al (2021) Imlifidase desensitization in Crossmatch-positive, highly sensitized kidney transplant recipients: results of an international phase 2 trial (Highdes). Transplantation 105(8):1808\u20131817. https:\/\/doi.org\/10.1097\/TP.0000000000003496","journal-title":"Transplantation"},{"key":"11_CR44","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1111\/ajt.17086","volume":"10","author":"SC Jordan","year":"2022","unstructured":"Jordan SC, Berg A, Shin B, Vo A, Ammerman N, Zhang R (2022a) Intravenous immunoglobulin contains high-titer neutralizing IgG antibodies to SARS-CoV-2. Am J Transplant 10:2484\u20132485","journal-title":"Am J Transplant"},{"issue":"Suppl 4","key":"11_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ajt.17207","volume":"22","author":"SC Jordan","year":"2022","unstructured":"Jordan SC, Ammerman N, Huang E, Vo A (2022b) Importance of IL-6 inhibition in prevention and treatment of antibody-mediated rejection in kidney allografts. Am J Transplant 22(Suppl 4):28\u201337. https:\/\/doi.org\/10.1111\/ajt.17207","journal-title":"Am J Transplant"},{"issue":"4","key":"11_CR46","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ekir.2022.01.1074","volume":"7","author":"SC Jordan","year":"2022","unstructured":"Jordan SC, Ammerman N, Choi J et al (2022c) Evaluation of Clazakizumab (anti-Interleukin-6) in patients with treatment-resistant chronic active antibody-mediated rejection of kidney allografts. Kidney Int Rep 7(4):720\u2013731. https:\/\/doi.org\/10.1016\/j.ekir.2022.01.1074","journal-title":"Kidney Int Rep"},{"issue":"6","key":"11_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajt.2024.05.005","volume":"24","author":"SC Jordan","year":"2024","unstructured":"Jordan SC, Maldonado A et al (2024) Long-term follow up of imlifidase desensitized kidney transplant recipients: 5 year pooled analysis. Am J Transplant 24(6):1","journal-title":"Am J Transplant"},{"issue":"38","key":"11_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.trim.2016.08.001","volume":"09","author":"I Kim","year":"2016","unstructured":"Kim I, Wu G, Chai NN, Klein AS, Jordan SC (2016) Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization. Transpl Immunol 09(38):84\u201392. https:\/\/doi.org\/10.1016\/j.trim.2016.08.001","journal-title":"Transpl Immunol"},{"issue":"2","key":"11_CR49","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/00007890-198108000-00019","volume":"32","author":"MG Kirubakaran","year":"1981","unstructured":"Kirubakaran MG, Disney AP, Norman J, Pugsley DJ, Mathew TH (1981) A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation 32(2):164\u2013165. https:\/\/doi.org\/10.1097\/00007890-198108000-00019","journal-title":"Transplantation"},{"issue":"12","key":"11_CR50","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1111\/ajt.16754","volume":"21","author":"C Kjellman","year":"2021","unstructured":"Kjellman C, Maldonado AQ, Sj\u00f6holm K et al (2021) Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. Am J Transplant 21(12):3907\u20133918. https:\/\/doi.org\/10.1111\/ajt.16754","journal-title":"Am J Transplant"},{"issue":"3","key":"11_CR51","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS et al (2016) Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128(3):384\u2013394. https:\/\/doi.org\/10.1182\/blood-2015-12-687749","journal-title":"Blood"},{"issue":"6, Supplement 1","key":"11_CR52","first-page":"S765","volume":"23","author":"MSK Kubo","year":"2023","unstructured":"Kubo MSK, Lu L, Vujevich V, Gunabushanam V, Ganoza A, Wijkstrom M, Humar A, Thomson A, Ezzelarab M (2023) IL-6 receptor blockade attenuates effector T cell function and significantly prolongs kidney allograft survival in CTLA4Ig-treated rhesus monkeys. AJT 23(6, Supplement 1):S765","journal-title":"AJT"},{"issue":"7","key":"11_CR53","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1681\/ASN.2018121254","volume":"30","author":"J Kwun","year":"2019","unstructured":"Kwun J, Matignon M, Manook M et al (2019) Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use. J Am Soc Nephrol 30(7):1206\u20131219. https:\/\/doi.org\/10.1681\/ASN.2018121254","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"11_CR54","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1038\/s41467-023-39859-7","volume":"14","author":"B Lamarth\u00e9e","year":"2023","unstructured":"Lamarth\u00e9e B, Callemeyn J, Van Herck Y et al (2023) Transcriptional and spatial profiling of the kidney allograft unravels a central role for FcyRIII+ innate immune cells in rejection. Nat Commun 14(1):4359. https:\/\/doi.org\/10.1038\/s41467-023-39859-7","journal-title":"Nat Commun"},{"issue":"2","key":"11_CR55","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1681\/ASN.2017050589","volume":"29","author":"C Lefaucheur","year":"2018","unstructured":"Lefaucheur C, Viglietti D, Hidalgo LG et al (2018) Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment. J Am Soc Nephrol 29(2):620\u2013635. https:\/\/doi.org\/10.1681\/ASN.2017050589","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"11_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222537","volume":"14","author":"JH Lim","year":"2019","unstructured":"Lim JH, Cho JH, Jung HY et al (2019) Excellent outcome after desensitization in high immunologic risk kidney transplantation. PLoS One 14(9):e0222537. https:\/\/doi.org\/10.1371\/journal.pone.0222537","journal-title":"PLoS One"},{"issue":"2","key":"11_CR57","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/TP.0b013e3182962c84","volume":"96","author":"AL Lobashevsky","year":"2013","unstructured":"Lobashevsky AL, Higgins NG, Rosner KM, Mujtaba MA, Goggins WC, Taber TE (2013) Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab. Transplantation 96(2):182\u2013190. https:\/\/doi.org\/10.1097\/TP.0b013e3182962c84","journal-title":"Transplantation"},{"issue":"2","key":"11_CR58","doi-asserted-by":"publisher","DOI":"10.1097\/txd.0000000000001436","volume":"9","author":"CM Looney","year":"2023","unstructured":"Looney CM, Schroeder A, Tavares E et al (2023) Obinutuzumab effectively depletes key B-cell subsets in blood and tissue in end-stage renal disease patients. Transplant Direct 9(2):e1436. https:\/\/doi.org\/10.1097\/txd.0000000000001436","journal-title":"Transplant Direct"},{"key":"11_CR59","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1056\/NEJMra1802677","volume":"379","author":"A Loupy","year":"2018","unstructured":"Loupy A, Lefaucheur C (2018) Antibody-mediated rejection of solid-organ allografts. N Engl J Med 379:1150\u20131160","journal-title":"N Engl J Med"},{"issue":"11","key":"11_CR60","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/TP.0b013e3181da1cc3","volume":"89","author":"A Loupy","year":"2010","unstructured":"Loupy A, Suberbielle-Boissel C, Zuber J et al (2010) Combined posttransplant prophylactic IVIg\/anti-CD 20\/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 89(11):1403\u20131410. https:\/\/doi.org\/10.1097\/TP.0b013e3181da1cc3","journal-title":"Transplantation"},{"issue":"7","key":"11_CR61","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1111\/ajt.12308","volume":"13","author":"RJ Lynch","year":"2013","unstructured":"Lynch RJ, Silva IA, Chen BJ, Punch JD, Cascalho M, Platt JL (2013) Cryptic B cell response to renal transplantation. Am J Transplant 13(7):1713\u20131723. https:\/\/doi.org\/10.1111\/ajt.12308","journal-title":"Am J Transplant"},{"key":"11_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660900","volume":"12","author":"M Manook","year":"2021","unstructured":"Manook M, Flores WJ, Schmitz R et al (2021) Measuring the impact of targeting FcRn-mediated IgG recycling on donor-specific alloantibodies in a sensitized NHP model. Front Immunol 12:660900. https:\/\/doi.org\/10.3389\/fimmu.2021.660900","journal-title":"Front Immunol"},{"key":"11_CR63","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa2400763","volume":"391","author":"KA Mayer","year":"2024","unstructured":"Mayer KA, Schrezenmeier E, Diebold M et al (2024) A randomized phase 2 trial of Felzartamab in antibody-mediated rejection. N Engl J Med 391:122\u2013132. https:\/\/doi.org\/10.1056\/NEJMoa2400763","journal-title":"N Engl J Med"},{"issue":"6","key":"11_CR64","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00007890-200009270-00006","volume":"70","author":"RA Montgomery","year":"2000","unstructured":"Montgomery RA, Zachary AA, Racusen LC et al (2000) Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70(6):887\u2013895. https:\/\/doi.org\/10.1097\/00007890-200009270-00006","journal-title":"Transplantation"},{"issue":"6","key":"11_CR65","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/tp.0000000000001330","volume":"101","author":"MA Moreno Gonzales","year":"2017","unstructured":"Moreno Gonzales MA, Gandhi MJ, Schinstock CA et al (2017) 32 doses of Bortezomib for desensitization is not well tolerated and is associated with only modest reductions in anti-HLA antibody. Transplantation 101(6):1222\u20131227. https:\/\/doi.org\/10.1097\/tp.0000000000001330","journal-title":"Transplantation"},{"key":"11_CR66","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/TP.0000000000003686","volume":"106","author":"MM NasrAllah","year":"2022","unstructured":"NasrAllah MM, Elalfy M, El Ansary M et al (2022) Obinutuzumab in kidney transplantation: effect on B-cell counts and crossmatch tests. Transplantation 106:369\u2013372. https:\/\/doi.org\/10.1097\/TP.0000000000003686","journal-title":"Transplantation"},{"key":"11_CR67","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/ajt.17210","volume":"22","author":"PW Nickerson","year":"2022","unstructured":"Nickerson PW (2022) Rationale for the IMAGINE study for chronic active antibody-mediated rejection (caAMR) in kidney transplantation. Am J Transplant 22:38\u201344. https:\/\/doi.org\/10.1111\/ajt.17210","journal-title":"Am J Transplant"},{"issue":"38","key":"11_CR68","doi-asserted-by":"publisher","first-page":"14502","DOI":"10.3389\/ti.2025.14502","volume":"16","author":"J Noble","year":"2025","unstructured":"Noble J, Comai G, Corredetti V, Laamech R, Dard C, Jouve T, Giovannini D, Le Gouellec A, Wadnerkar S, Cravedi P, Apuzzo D, Vetrano D, Busutti M, Abenavoli C, Malvezzi P, Rostaing LP, Lamanna G (2025) Tocilizumab-based treatment of microvascular inflammation in kidney transplant recipients: a retrospective study. Transpl Int 16(38):14502. https:\/\/doi.org\/10.3389\/ti.2025.14502. PMID: 40454296; PMCID: PMC12124137","journal-title":"Transpl Int"},{"issue":"23","key":"11_CR69","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","volume":"392","author":"RJ Nowak","year":"2025","unstructured":"Nowak RJ, Benatar M, Ciafaloni E, Howard JF Jr, Leite MI, Utsugisawa K, Vissing J, Rojavin M, Li Q, Tang F, Wu Y, Rampal N, Cheng S, Investigators MINT (2025) A phase 3 trial of Inebilizumab in generalized myasthenia gravis. N Engl J Med 392(23):2309\u20132320. https:\/\/doi.org\/10.1056\/NEJMoa2501561. Epub 2025 Apr 8","journal-title":"N Engl J Med"},{"issue":"8","key":"11_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14734","volume":"36","author":"M Pearl","year":"2022","unstructured":"Pearl M, Weng PL, Chen L, Dokras A, Pizzo H, Garrison J, Butler C, Zhang J, Reed EF, Kim IK, Choi J, Haas M, Zhang X, Vo A, Chambers ET, Ettenger R, Jordan S, Puliyanda D (2022) Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients. Clin Transpl 36(8):e14734. https:\/\/doi.org\/10.1111\/ctr.14734. Epub 2022 Jun 12. PMID: 35657013; PMCID: PMC9378624","journal-title":"Clin Transpl"},{"issue":"3s","key":"11_CR71","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","volume":"139","author":"EE Perez","year":"2017","unstructured":"Perez EE, Orange JS, Bonilla F et al (2017) Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 139(3s):S1\u2013s46. https:\/\/doi.org\/10.1016\/j.jaci.2016.09.023","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"11_CR72","doi-asserted-by":"publisher","DOI":"10.1097\/txd.0000000000001131","volume":"7","author":"C Pham","year":"2021","unstructured":"Pham C, Pierce BJ, Nguyen DT, Graviss EA, Huang HJ (2021) Assessment of Carfilzomib treatment response in lung transplant recipients with antibody-mediated rejection. Transplant Direct 7(4):e680. https:\/\/doi.org\/10.1097\/txd.0000000000001131","journal-title":"Transplant Direct"},{"issue":"2","key":"11_CR73","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/TP.0000000000004784","volume":"108","author":"AA Pottebaum","year":"2024","unstructured":"Pottebaum AA, January SE, Liu C, Lavine S, Schilling JD, Lavine KJ (2024) Feasibility of Interleukin-6 receptor blockade in cardiac antibody-mediated rejection. Transplantation 108(2):539\u2013544. https:\/\/doi.org\/10.1097\/TP.0000000000004784. Epub 2023 Aug 29. PMID: 37638881; PMCID: PMC10798586","journal-title":"Transplantation"},{"issue":"11","key":"11_CR74","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1111\/ajt.15514","volume":"19","author":"RR Redfield","year":"2019","unstructured":"Redfield RR, Jordan SC, Busque S et al (2019) Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. Am J Transplant 19(11):3035\u20133045. https:\/\/doi.org\/10.1111\/ajt.15514","journal-title":"Am J Transplant"},{"key":"11_CR75","unstructured":"Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS) (n.d.). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04935177"},{"issue":"17","key":"11_CR76","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/bloodadvances.2018020644","volume":"2","author":"A Roth","year":"2018","unstructured":"Roth A, Rottinghaus ST, Hill A et al (2018) Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies. Blood Adv 2(17):2176\u20132185. https:\/\/doi.org\/10.1182\/bloodadvances.2018020644","journal-title":"Blood Adv"},{"issue":"5","key":"11_CR77","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1053\/j.ajkd.2022.11.010","volume":"81","author":"RE Scalzo","year":"2023","unstructured":"Scalzo RE, Sanoff SL, Rege AS et al (2023) Daratumumab use prior to kidney transplant and T cell-mediated rejection: a case report. Am J Kidney Dis 81(5):616\u2013620. https:\/\/doi.org\/10.1053\/j.ajkd.2022.11.010","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"11_CR78","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/TP.0000000000003095","volume":"104","author":"CA Schinstock","year":"2020","unstructured":"Schinstock CA, Mannon RB et al (2020) Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the transplantation society working group. Transplantation 104(5):911\u2013922. https:\/\/doi.org\/10.1097\/TP.0000000000003095","journal-title":"Transplantation"},{"issue":"3","key":"11_CR79","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000538513","volume":"51","author":"E Schrezenmeier","year":"2024","unstructured":"Schrezenmeier E, Choi M, Globke B et al (2024) Successful desensitization with Imlifidase and Daratumumab in a highly immunized, crossmatch positive, blood group-incompatible living-donor re-transplant recipient with systemic lupus erythematosus and antiphospholipid syndrome. Transfus Med Hemother 51(3):158\u2013163. https:\/\/doi.org\/10.1159\/000538513","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"11_CR80","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1038\/s41598-018-23481-5","volume":"8","author":"J Seijsing","year":"2018","unstructured":"Seijsing J, Yu S, Frejd FY, H\u00f6iden-Guthenberg I, Gr\u00e4slund T (2018) In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor. Sci Rep 8(1):5141. https:\/\/doi.org\/10.1038\/s41598-018-23481-5","journal-title":"Sci Rep"},{"issue":"1","key":"11_CR81","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/imr.12331","volume":"268","author":"NM Stapleton","year":"2015","unstructured":"Stapleton NM, Einarsd\u00f3ttir HK, Stemerding AM, Vidarsson G (2015) The multiple facets of FcRn in immunity. Immunol Rev 268(1):253\u2013268. https:\/\/doi.org\/10.1111\/imr.12331","journal-title":"Immunol Rev"},{"issue":"11","key":"11_CR82","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","volume":"11","author":"MD Stegall","year":"2011","unstructured":"Stegall MD, Diwan T, Raghavaiah S et al (2011) Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11(11):2405\u20132413. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03757.x","journal-title":"Am J Transplant"},{"issue":"1","key":"11_CR83","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13063-024-08020-0","volume":"25","author":"L Streichart","year":"2024","unstructured":"Streichart L, Felldin M, Ekberg J, Mj\u00f6rnstedt L, Lindn\u00e9r P, Lennerling A, Br\u00f6cker V, M\u00f6lne J, Holgersson J, Daenen K, Wennberg L, Lorant T, Baid-Agrawal S (2024) Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study). Trials 25(1):213. https:\/\/doi.org\/10.1186\/s13063-024-08020-0. PMID: 38519988; PMCID: PMC10958896","journal-title":"Trials"},{"key":"11_CR84","unstructured":"Study for Desensitization of Chronic Kidney Disease in Adult Patients in Need of a Kidney Transplant Who Are Highly Sensitized to Human Leukocyte Antigen (n.d.). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05092347"},{"issue":"10","key":"11_CR85","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6(10):a016295. https:\/\/doi.org\/10.1101\/cshperspect.a016295","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"11_CR86","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5672523","volume":"2017","author":"M Toyoda","year":"2017","unstructured":"Toyoda M, Shin BH, Ge S et al (2017) Impact of desensitization on antiviral immunity in HLA-sensitized kidney transplant recipients. J Immunol Res 2017:5672523. https:\/\/doi.org\/10.1155\/2017\/5672523","journal-title":"J Immunol Res"},{"issue":"2","key":"11_CR87","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ajt.15613","volume":"20","author":"S Tremblay","year":"2020","unstructured":"Tremblay S, Driscoll JJ, Rike-Shields A et al (2020) A prospective, iterative, adaptive trial of carfilzomib-based desensitization. Am J Transplant 20(2):411\u2013421. https:\/\/doi.org\/10.1111\/ajt.15613","journal-title":"Am J Transplant"},{"key":"11_CR88","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.imlet.2018.04.005","volume":"199","author":"NWCJ van de Donk","year":"2018","unstructured":"van de Donk NWCJ (2018) Immunomodulatory effects of CD38-targeting antibodies. Immunol Lett 199:16\u201322. https:\/\/doi.org\/10.1016\/j.imlet.2018.04.005","journal-title":"Immunol Lett"},{"issue":"2","key":"11_CR89","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ajt.13052","volume":"15","author":"MW van den Hoogen","year":"2015","unstructured":"van den Hoogen MW, Kamburova EG, Baas MC et al (2015) Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Transplant 15(2):407\u2013416. https:\/\/doi.org\/10.1111\/ajt.13052","journal-title":"Am J Transplant"},{"issue":"5","key":"11_CR90","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1111\/ajt.13663","volume":"16","author":"D Viglietti","year":"2016","unstructured":"Viglietti D, Gosset C, Loupy A et al (2016) C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study. Am J Transplant 16(5):1596\u20131603. https:\/\/doi.org\/10.1111\/ajt.13663","journal-title":"Am J Transplant"},{"issue":"4","key":"11_CR91","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMoa1506027","volume":"374","author":"F Vincenti","year":"2016","unstructured":"Vincenti F, Rostaing L, Grinyo J et al (2016) Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374(4):333\u2013343. https:\/\/doi.org\/10.1056\/NEJMoa1506027","journal-title":"N Engl J Med"},{"issue":"3","key":"11_CR92","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJMoa0707894","volume":"359","author":"AA Vo","year":"2008","unstructured":"Vo AA, Lukovsky M, Toyoda M et al (2008) Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359(3):242\u2013251. https:\/\/doi.org\/10.1056\/NEJMoa0707894","journal-title":"N Engl J Med"},{"issue":"6","key":"11_CR93","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1097\/TP.0b013e3182802f88","volume":"95","author":"AA Vo","year":"2013","unstructured":"Vo AA, Petrozzino J, Yeung K et al (2013) Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 95(6):852\u2013858. https:\/\/doi.org\/10.1097\/TP.0b013e3182802f88","journal-title":"Transplantation"},{"issue":"11","key":"11_CR94","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1097\/TP.0000000000000741","volume":"99","author":"AA Vo","year":"2015","unstructured":"Vo AA, Choi J, Kim I et al (2015a) A phase I\/II trial of the Interleukin-6 receptor-specific humanized monoclonal (Tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation 99(11):2356\u20132363. https:\/\/doi.org\/10.1097\/TP.0000000000000741","journal-title":"Transplantation"},{"issue":"2","key":"11_CR95","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/TP.0000000000000592","volume":"99","author":"AA Vo","year":"2015","unstructured":"Vo AA, Zeevi A, Choi J et al (2015b) A phase I\/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation 99(2):299\u2013308. https:\/\/doi.org\/10.1097\/TP.0000000000000592","journal-title":"Transplantation"},{"issue":"4","key":"11_CR96","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/ajt.16926","volume":"22","author":"AA Vo","year":"2022","unstructured":"Vo AA, Huang E, Ammerman N et al (2022) Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. Am J Transplant 22(4):1133\u20131144. https:\/\/doi.org\/10.1111\/ajt.16926","journal-title":"Am J Transplant"},{"issue":"8","key":"11_CR97","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.34067\/KID.0000000000000509","volume":"5","author":"A Vo","year":"2024","unstructured":"Vo A, Ammerman N, Jordan SC (2024) New therapies for highly sensitized patients on the waiting list. Kidney360 5(8):1207\u20131225. https:\/\/doi.org\/10.34067\/KID.0000000000000509","journal-title":"Kidney360"},{"issue":"9","key":"11_CR98","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1111\/ajt.14256","volume":"17","author":"M Wahrmann","year":"2017","unstructured":"Wahrmann M, Muhlbacher J, Marinova L et al (2017) Effect of the anti-C1s humanized antibody TNT009 and its parental mouse variant TNT003 on HLA antibody-induced complement activation-a preclinical in vitro study. Am J Transplant 17(9):2300\u20132311. https:\/\/doi.org\/10.1111\/ajt.14256","journal-title":"Am J Transplant"},{"issue":"3","key":"11_CR99","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/ajt.14015","volume":"17","author":"C Wiebe","year":"2017","unstructured":"Wiebe C, Gareau AJ, Pochinco D et al (2017) Evaluation of C1q status and titer of De Novo donor-specific antibodies as predictors of allograft survival. Am J Transplant 17(3):703\u2013711. https:\/\/doi.org\/10.1111\/ajt.14015","journal-title":"Am J Transplant"},{"issue":"5","key":"11_CR100","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/TP.0b013e31827be3c1","volume":"95","author":"AA Zachary","year":"2013","unstructured":"Zachary AA, Lucas DP, Montgomery RA, Leffell MS (2013) Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. Transplantation 95(5):701\u2013704. https:\/\/doi.org\/10.1097\/TP.0b013e31827be3c1","journal-title":"Transplantation"},{"issue":"11","key":"11_CR101","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1097\/TP.0000000000003849","volume":"105","author":"X Zhang","year":"2021","unstructured":"Zhang X, Li F, Jordan SC (2021) Obinutuzumab in kidney transplantation: effect on B-cell counts and crossmatch tests. Transplantation 105(11):e272\u2013e273. https:\/\/doi.org\/10.1097\/TP.0000000000003849. PMID: 34709221","journal-title":"Transplantation"},{"issue":"12","key":"11_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101336","volume":"4","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Markmann C, Yu M et al (2023) Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies. Cell Rep Med 4(12):101336. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101336","journal-title":"Cell Rep Med"},{"issue":"6","key":"11_CR103","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s11255-013-0599-4","volume":"46","author":"YG Zhao","year":"2014","unstructured":"Zhao YG, Shi BY, Qian YY, Bai HW, Xiao L, He XY (2014) Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis. Int Urol Nephrol 46(6):1225\u20131230. https:\/\/doi.org\/10.1007\/s11255-013-0599-4","journal-title":"Int Urol Nephrol"}],"container-title":["Results and Problems in Cell Differentiation","Cellular and Molecular Mechanisms of Chronic Rejection in Organ Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-07686-1_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T23:39:51Z","timestamp":1767310791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-07686-1_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032076854","9783032076861"],"references-count":103,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-07686-1_11","relation":{},"ISSN":["0080-1844","1861-0412"],"issn-type":[{"value":"0080-1844","type":"print"},{"value":"1861-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"2 January 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}